JP2019534277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534277A5 JP2019534277A5 JP2019520869A JP2019520869A JP2019534277A5 JP 2019534277 A5 JP2019534277 A5 JP 2019534277A5 JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019534277 A5 JP2019534277 A5 JP 2019534277A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- amino acid
- acid sequence
- sequence
- antibody construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 112
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 230000003993 interaction Effects 0.000 claims description 48
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 230000035772 mutation Effects 0.000 claims description 44
- 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 claims description 23
- 101710119577 Molybdopterin molybdenumtransferase Proteins 0.000 claims description 23
- 238000012986 modification Methods 0.000 claims description 17
- 230000004048 modification Effects 0.000 claims description 17
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162426A JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410054P | 2016-10-19 | 2016-10-19 | |
| US62/410,054 | 2016-10-19 | ||
| US201762549894P | 2017-08-24 | 2017-08-24 | |
| US62/549,894 | 2017-08-24 | ||
| US201762555498P | 2017-09-07 | 2017-09-07 | |
| US62/555,498 | 2017-09-07 | ||
| PCT/US2017/057268 WO2018075692A2 (en) | 2016-10-19 | 2017-10-18 | Antibody constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162426A Division JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534277A JP2019534277A (ja) | 2019-11-28 |
| JP2019534277A5 true JP2019534277A5 (enExample) | 2020-11-26 |
| JP7261158B2 JP7261158B2 (ja) | 2023-04-19 |
Family
ID=60452719
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520869A Active JP7261158B2 (ja) | 2016-10-19 | 2017-10-18 | 抗体構築物 |
| JP2022162426A Active JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162426A Active JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180118811A1 (enExample) |
| EP (1) | EP3529269B1 (enExample) |
| JP (2) | JP7261158B2 (enExample) |
| KR (3) | KR20250044934A (enExample) |
| CN (3) | CN118359705A (enExample) |
| AU (1) | AU2017345454B2 (enExample) |
| CA (1) | CA3041254A1 (enExample) |
| IL (1) | IL266143A (enExample) |
| MX (1) | MX421186B (enExample) |
| WO (1) | WO2018075692A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
| WO2017100372A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| WO2017218707A2 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| KR20250044934A (ko) * | 2016-10-19 | 2025-04-01 | 인벤라 인코포레이티드 | 항체 구조물 |
| WO2019183406A1 (en) * | 2018-03-21 | 2019-09-26 | Invenra Inc. | Multispecific antibody purification with ch1 resin |
| BR112020019795A2 (pt) | 2018-03-30 | 2021-01-05 | Merus N.V. | Anticorpo multivalente |
| WO2019204522A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Binding molecules |
| MY207121A (en) | 2018-04-18 | 2025-01-31 | Exelixis Inc | Anti-ror antibody constructs |
| JP7193628B2 (ja) * | 2018-07-06 | 2022-12-20 | 北京天成新脉生物技▲術▼有限公司 | 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用 |
| US20220213225A1 (en) * | 2018-07-30 | 2022-07-07 | Invenra Inc. | Multispecific treg binding molecules |
| JP7596263B2 (ja) * | 2018-10-10 | 2024-12-09 | ザイムワークス ビーシー インコーポレイテッド | ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 |
| CN113795508A (zh) | 2018-12-24 | 2021-12-14 | 赛诺菲 | 具有突变型Fab结构域的多特异性结合蛋白 |
| CA3171363A1 (en) * | 2019-12-20 | 2021-06-24 | Kisoji Biotechnology Inc. | Polypeptides, protein complexes and method for making same |
| IL295749A (en) * | 2020-02-20 | 2022-10-01 | Win Therapeutics Inc | Bispecific molecules binding gd2 and b7h2 and methods of use |
| MX2023006899A (es) * | 2020-12-10 | 2023-09-04 | Invenra Inc | Mutaciones ortogonales para heterodimerización. |
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| TW202506726A (zh) * | 2023-04-07 | 2025-02-16 | 美商麥迪紐有限責任公司 | 雙特異性工程化抗體 |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8905551D0 (en) * | 1989-03-10 | 1989-04-19 | Unilever Plc | Detergent compositions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| CN104998273A (zh) | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| CA2587589A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| KR20080080482A (ko) | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| TWI543768B (zh) | 2007-11-30 | 2016-08-01 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| US8491880B2 (en) | 2008-12-10 | 2013-07-23 | Mersana Therapeutics, Inc. | Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates |
| JP2012528240A (ja) | 2009-05-28 | 2012-11-12 | メルサナ セラピューティックス， インコーポレイテッド | 可変速度放出リンカーを含むポリアル−薬物コンジュゲート |
| KR101947176B1 (ko) | 2009-06-03 | 2019-02-12 | 이뮤노젠 아이엔씨 | 접합 방법 |
| EP2538973A2 (en) | 2010-02-26 | 2013-01-02 | Novo Nordisk A/S | Stable antibody containing compositions |
| JP5919606B2 (ja) | 2010-11-11 | 2016-05-18 | アッヴィ バイオテクノロジー リミテッド | 改良型高濃度抗ｔｎｆアルファ抗体液体製剤 |
| KR101962483B1 (ko) * | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| JP5830085B2 (ja) | 2011-03-10 | 2015-12-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｏａｔｐ１ｂ１の輸送活性を促進又は阻害する化合物をスクリーニングするための方法、及びｏａｔｐ１ｂ１発現量を測定するための方法 |
| BR112013031819B1 (pt) | 2011-06-10 | 2022-05-03 | Mersana Therapeutics, Inc | Suporte polimérico, composição farmacêutica, composto, e, uso do suporte |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| EP2748197A2 (en) * | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| PT2794905T (pt) | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
| PT2838917T (pt) * | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
| KR102557309B1 (ko) | 2012-05-15 | 2023-07-20 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| AU2013334740A1 (en) | 2012-10-25 | 2015-04-02 | Medimmune, Llc | Stable, low viscosity antibody formulation |
| JP6334553B2 (ja) | 2012-12-10 | 2018-05-30 | メルサナ セラピューティクス，インコーポレイティド | タンパク質−高分子−薬剤コンジュゲート |
| US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| WO2014160360A1 (en) | 2013-03-14 | 2014-10-02 | Mersana Therapeutics Inc. | Tubulysin compounds and conjugates thereof |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| AU2014337555C1 (en) | 2013-10-15 | 2021-01-28 | Seagen Inc. | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
| US11116847B2 (en) | 2013-12-19 | 2021-09-14 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
| MX385823B (es) | 2014-02-17 | 2025-03-18 | Seagen Inc | Conjugados de anticuerpo-farmaco hidrofilicos. |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| JP2017512814A (ja) | 2014-04-07 | 2017-05-25 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤 |
| WO2015195925A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| TWI551060B (zh) * | 2014-09-24 | 2016-09-21 | 衡宇科技股份有限公司 | Ｂｃｈ解碼方法及其解碼器 |
| WO2016087650A1 (en) * | 2014-12-05 | 2016-06-09 | Merck Patent Gmbh | Domain-exchanged antibody |
| WO2016180941A1 (en) | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
| EP3325483B1 (en) | 2015-07-21 | 2019-10-02 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| KR20180105233A (ko) | 2016-02-05 | 2018-09-27 | 이뮤노젠 아이엔씨 | 세포 결합제-세포독성제 접합체를 제조하기 위한 효율적인 방법 |
| US10947317B2 (en) | 2016-03-15 | 2021-03-16 | Mersana Therapeutics, Inc. | NaPi2b-targeted antibody-drug conjugates and methods of use thereof |
| KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| EP3241531A1 (en) * | 2016-05-04 | 2017-11-08 | noonee AG | Leg unit for a wearable sitting posture assisting device |
| KR20250044934A (ko) * | 2016-10-19 | 2025-04-01 | 인벤라 인코포레이티드 | 항체 구조물 |
| US20210179734A1 (en) * | 2018-04-17 | 2021-06-17 | Invenra Inc. | Trivalent trispecific antibody constructs |
| WO2019204522A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Binding molecules |
| MY207121A (en) * | 2018-04-18 | 2025-01-31 | Exelixis Inc | Anti-ror antibody constructs |
| US20220213225A1 (en) * | 2018-07-30 | 2022-07-07 | Invenra Inc. | Multispecific treg binding molecules |
| WO2021145946A1 (en) * | 2020-01-13 | 2021-07-22 | Invenra Inc. | Multispecific treg binding molecules |
-
2017
- 2017-10-18 KR KR1020257008855A patent/KR20250044934A/ko active Pending
- 2017-10-18 AU AU2017345454A patent/AU2017345454B2/en active Active
- 2017-10-18 MX MX2019004690A patent/MX421186B/es unknown
- 2017-10-18 CA CA3041254A patent/CA3041254A1/en active Pending
- 2017-10-18 JP JP2019520869A patent/JP7261158B2/ja active Active
- 2017-10-18 KR KR1020197013738A patent/KR102617264B1/ko active Active
- 2017-10-18 CN CN202410343134.7A patent/CN118359705A/zh active Pending
- 2017-10-18 KR KR1020237043908A patent/KR20240000650A/ko active Pending
- 2017-10-18 US US15/787,640 patent/US20180118811A1/en not_active Abandoned
- 2017-10-18 EP EP17804323.8A patent/EP3529269B1/en active Active
- 2017-10-18 WO PCT/US2017/057268 patent/WO2018075692A2/en not_active Ceased
- 2017-10-18 CN CN201780078920.7A patent/CN110177805B/zh active Active
- 2017-10-18 CN CN202410332902.9A patent/CN118359704A/zh active Pending
-
2019
- 2019-04-18 IL IL266143A patent/IL266143A/en unknown
-
2022
- 2022-10-07 JP JP2022162426A patent/JP7591015B2/ja active Active
- 2022-11-15 US US18/055,720 patent/US20240043502A1/en not_active Abandoned